Stock Analysis on Net
Stock Analysis on Net

Allergan Inc. (NYSE:AGN.)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 19, 2015.

Common-Size Income Statement

Paying user area

Try for free

Allergan Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Allergan Inc., common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Product net sales
Cost of sales, excludes amortization of intangible assets
Amortization of intangible assets
Gross profit
Other revenues
Selling, general and administrative
Research and development
Legal settlement
Impairment of intangible assets and related costs
Restructuring charges
Operating income
Interest income
Interest expense
Other, net
Non-operating income (expense)
Earnings from continuing operations before income taxes
Provision for income taxes
Earnings from continuing operations
Earnings from discontinued operations, net of applicable income tax
Loss on sale of discontinued operations, net of applicable income tax
Discontinued operations
Net earnings
Net earnings attributable to noncontrolling interest
Net earnings attributable to Allergan, Inc.

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

Income statement item Description The company
Operating income The net result for the period of deducting operating expenses from operating revenues. Allergan Inc. operating income as a percentage of product net sales increased from 2012 to 2013 but then decreased significantly from 2013 to 2014.
Earnings from continuing operations before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Allergan Inc. earnings from continuing operations before income taxes as a percentage of product net sales increased from 2012 to 2013 but then slightly decreased from 2013 to 2014.
Net earnings attributable to Allergan, Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Allergan Inc. net earnings attributable to Allergan, Inc. as a percentage of product net sales decreased from 2012 to 2013 but then increased from 2013 to 2014 exceeding 2012 level.